Showing all 3 results
Alfuzosin Hydrochloride Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Extended-Release (ER) Tablet, packed in high-barrier Alu-Alu blister strips to ensure API stability.
Active Ingredient Strength Primary Clinical Function Alfuzosin Hydrochloride USP/BP 10 mg The Standard Therapeutic Anchor: The globally validated once-daily dose for moderate-to-severe BPH symptoms. Excipients Extended-Release Matrix Controlled-Delivery System: Engineered to provide synchronized 24-hour therapeutic coverage, eliminating the need for multiple daily doses. Bethanecol Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Bioavailability Tablet, packed in secure Alu-PVC or Alu-Alu blister strips.
Active Ingredient Strength Primary Clinical Function Bethanechol Chloride USP/BP 10 mg The Pediatric & Titration Unit: Ideal for initial dosing or mild cases of gastric atony. Bethanechol Chloride USP/BP 25 mg The Urology Anchor: The standardized therapeutic dose for managing post-operative urinary retention. Excipients Proprietary Matrix Acid-Stable Formulation: Engineered to survive the gastric environment for consistent intestinal absorption. Bicalutamide Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Cytotoxic Tablet, packed in high-barrier Alu-Alu blister strips to ensure the stability of the active API.
Active Ingredient Strength Primary Clinical Function Bicalutamide USP/Ph.Eur. 50 mg The Metastatic Anchor: Used in combination with a LHRH analogue (medical castration) for advanced metastatic disease. Bicalutamide USP/Ph.Eur. 150 mg The Monotherapy Payload: Utilized as a standalone treatment for locally advanced, non-metastatic prostate cancer. Excipients Proprietary Matrix High-Containment Coating: Engineered with an impenetrable film-coat to prevent the release of cytotoxic dust during handling by healthcare professionals.
